GDRXHIGH SIGNALFINANCIAL10-K

GoodRx experienced a dramatic doubling of current liabilities alongside substantial cash burn, indicating potential liquidity pressures despite improved profitability.

The company's current liabilities doubled to $246M while cash declined by over 40% to $262M, creating a concerning shift in the near-term financial position that could constrain operational flexibility. Despite meaningfully higher net income and operating performance, the balance sheet deterioration suggests underlying working capital challenges or significant short-term obligations that warrant close monitoring.

Comparing 2026-02-26 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

GoodRx delivered notably stronger profitability with net income substantially higher year-over-year and operating income growing over 30%, indicating improved operational execution. However, the balance sheet tells a more concerning story with current liabilities doubling while cash reserves declined significantly, creating potential near-term liquidity constraints. The company continued aggressive share buybacks at $216M, which may have contributed to the cash decline, though the dramatic increase in current liabilities suggests other factors are driving the balance sheet deterioration.

FINANCIAL STATEMENT CHANGES
Current Liabilities
Balance Sheet
+98.5%
$123.9M→$246.0M

Current liabilities surged 98.5% — significant near-term obligations; verify ability to meet short-term debt.

Net Income
P&L
+85.7%
$16.4M→$30.4M

Net income grew 85.7% — bottom-line growth signals improving overall business health.

Accounts Receivable
Balance Sheet
+61.5%
$145.9M→$235.7M

Receivables surged 61.5% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Cash & Equivalents
Balance Sheet
-41.6%
$448.3M→$261.8M

Cash declined 41.6% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Share Buybacks
Cash Flow
+36.2%
$158.8M→$216.4M

Share repurchases increased 36.2% — management returning capital, signals confidence in intrinsic value.

Operating Income
P&L
+32.9%
$65.8M→$87.5M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Total Liabilities
Balance Sheet
+18.7%
$663.4M→$787.8M

Liabilities increased 18.7% — monitor debt-to-equity ratio and interest coverage.

Stockholders Equity
Balance Sheet
-15%
$724.7M→$616.3M

Equity decreased 15% — buybacks or losses reducing book value, monitor solvency ratios.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-27
ADDED
As of February 17, 2026 the registrant had 108,610,311 shares of Class A common stock, $0.0001 par value per share, and 233,964,187 shares of Class B common stock, $0.0001 par value, outstanding.
Co-Founders refers to Trevor Bezdek and Douglas Hirsch, each a director of the Company.
The term discounted price excludes prices we may otherwise source, such as prices from patient assistance programs for low-income individuals and Medicare prices, and any negotiated rates offered through our subscription offerings.
Monthly Active Consumers do not include subscribers to our subscription offerings, consumers of our GoodRx Pharma Direct (formerly pharma manufacturer solutions and referred to hereafter as "pharma direct") offering, or consumers who used our telehealth offering.
Effective January 1, 2025, Monthly Active Consumers from acquired companies are included beginning from the acquisition date.
+7 more — sign up free →
REMOVED
As of February 18, 2025 the registrant had 106,740,328 shares of Class A common stock, $0.0001 par value per share, and 276,869,320 shares of Class B common stock, $0.0001 par value, outstanding.
Co-Founders refers to Trevor Bezdek, our Co- Chairman and a director of the Company, and Douglas Hirsch, a director of the Company.
The term discounted price excludes prices we may otherwise source, such as prices from patient assistance programs for low-income individuals and Medicare prices, and any negotiated rates offered through our subscription offerings: GoodRx Gold ( Gold ), and Kroger Rx Savings Club powered by GoodRx ( Kroger Savings ) which sunset in July 2024.
Monthly Active Consumers do not include subscribers to our subscription offerings, consumers of our pharma manufacturer solutions offering, or consumers who used our telehealth offering.
Monthly Active Consumers from acquired companies are only included beginning in the first full quarter following the acquisition.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →